Although various previous studies have reported the pathogenic role of NF-κβ/ TLR-4 and SERCA/Ca2 + pathways and, subsequently, clinical and therapeutic benefits of AGE against DM, there is an urgent need to identify the potential hotspot targeted by therapeutically active compounds present in AGE[29, 30]. This evidence concerns the gene NFKB1 and diabetes mellitus.